Studies of Mitomycin C Absorption After Intravesical Treatment of Superficial Bladder Tumors
- 1 July 1984
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 132 (1) , 30-32
- https://doi.org/10.1016/s0022-5347(17)49450-x
Abstract
Mitomycin C is an active drug in the treatment of superficial bladder cancer. Although clinical safety of intravesical mitomycin C was well accepted there are no data on absorption of this drug from the bladder in patients with damaged bladder mucosa. Patients (18) were studied for evidence of absorption of mitomycin C after transurethral resection and/or radiation therapy. Mitomycin C is absorbed on intravesical instillation and the degree of absorption depends on the degree of damage to the bladder. Despite some evidence of absorption no systemic effect on bone marrow was observed and no evidence of DNA damage was found in any of these patients. Mitomycin C appears to be a safe drug but further studies are indicated to document its safety when used for maintenance therapy.This publication has 4 references indexed in Scilit:
- Effects of mitomycin C on sister chromatid exchange in normal and bloom's syndrome cellsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1978
- Sister chromatid exchanges—A sensitive assay of agents damaging human chromosomesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1975
- New Giemsa method for the differential staining of sister chromatidsNature, 1974